Citigroup’s Akebia Therapeutics AKBA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.97M | Buy |
2,854,586
+418,383
| +17% | +$575K | ﹤0.01% | 2140 |
|
|
2025
Q4 | $3.92M | Buy |
2,436,203
+519,511
| +27% | +$1.09M | ﹤0.01% | 2192 |
|
|
2025
Q3 | $5.23M | Buy |
1,916,692
+1,782,162
| +1,325% | +$5.93M | ﹤0.01% | 1938 |
|
|
2025
Q2 | $490K | Sell |
134,530
-171,470
| -56% | -$471K | ﹤0.01% | 3641 |
|
|
2025
Q1 | $588K | Buy |
306,000
+69,214
| +29% | +$141K | ﹤0.01% | 3586 |
|
|
2024
Q4 | $450K | Buy |
236,786
+85,381
| +56% | +$148K | ﹤0.01% | 3900 |
|
|
2024
Q3 | $200K | Buy |
151,405
+104,845
| +225% | +$140K | ﹤0.01% | 4342 |
|
|
2024
Q2 | $47.5K | Sell |
46,560
-141,265
| -75% | -$175K | ﹤0.01% | 4613 |
|
|
2024
Q1 | $344K | Sell |
187,825
-117,781
| -39% | -$188K | ﹤0.01% | 3771 |
|
|
2023
Q4 | $379K | Buy |
305,606
+152,869
| +100% | +$156K | ﹤0.01% | 3588 |
|
|
2023
Q3 | $174K | Buy |
152,737
+152,688
| +311,608% | +$196K | ﹤0.01% | 3725 |
|
|
2023
Q2 | $45 | Hold |
49
| – | – | ﹤0.01% | 5473 |
|
|
2023
Q1 | $27 | Sell |
49
-677
| -93% | -$517 | ﹤0.01% | 5360 |
|
|
2022
Q4 | $419 | Sell |
726
-45,897
| -98% | -$14.4K | ﹤0.01% | 5530 |
|
|
2022
Q3 | $15K | Sell |
46,623
-63,664
| -58% | -$25K | ﹤0.01% | 4837 |
|
|
2022
Q2 | $39K | Sell |
110,287
-126,503
| -53% | -$53.1K | ﹤0.01% | 4645 |
|
|
2022
Q1 | $170K | Sell |
236,790
-439,396
| -65% | -$940K | ﹤0.01% | 4161 |
|
|
2021
Q4 | $1.53M | Buy |
676,186
+227,543
| +51% | +$620K | ﹤0.01% | 2842 |
|
|
2021
Q3 | $1.29M | Sell |
448,643
-464,125
| -51% | -$1.33M | ﹤0.01% | 2887 |
|
|
2021
Q2 | $3.46M | Sell |
912,768
-221,780
| -20% | -$747K | ﹤0.01% | 2233 |
|
|
2021
Q1 | $3.84M | Buy |
1,134,548
+1,090,721
| +2,489% | +$3.93M | ﹤0.01% | 1981 |
|
|
2020
Q4 | $123K | Buy |
43,827
+28,335
| +183% | +$82.7K | ﹤0.01% | 5371 |
|
|
2020
Q3 | $39K | Sell |
15,492
-592,605
| -97% | -$5.2M | ﹤0.01% | 5741 |
|
|
2020
Q2 | $8.26M | Buy |
608,097
+509,968
| +520% | +$5.28M | 0.01% | 1450 |
|
|
2020
Q1 | $744K | Buy |
98,129
+30,762
| +46% | +$239K | ﹤0.01% | 3484 |
|
|
2019
Q4 | $425K | Sell |
67,367
-256,337
| -79% | -$1.22M | ﹤0.01% | 4567 |
|
|
2019
Q3 | $1.27M | Sell |
323,704
-17,508
| -5% | -$75K | ﹤0.01% | 3369 |
|
|
2019
Q2 | $1.65M | Buy |
341,212
+302,319
| +777% | +$1.72M | ﹤0.01% | 3080 |
|
|
2019
Q1 | $318K | Sell |
38,893
-258,612
| -87% | -$1.77M | ﹤0.01% | 4646 |
|
|
2018
Q4 | $1.65M | Buy |
297,505
+245,988
| +477% | +$1.93M | ﹤0.01% | 2862 |
|
|
2018
Q3 | $455K | Buy |
51,517
+7,052
| +16% | +$63.1K | ﹤0.01% | 4396 |
|
|
2018
Q2 | $444K | Buy |
44,465
+8,606
| +24% | +$86.2K | ﹤0.01% | 4248 |
|
|
2018
Q1 | $342K | Sell |
35,859
-6,413
| -15% | -$89.7K | ﹤0.01% | 4386 |
|
|
2017
Q4 | $629K | Buy |
42,272
+14,971
| +55% | +$248K | ﹤0.01% | 3865 |
|
|
2017
Q3 | $537K | Buy |
27,301
+23,321
| +586% | +$359K | ﹤0.01% | 4046 |
|
|
2017
Q2 | $57K | Buy |
3,980
+3,658
| +1,136% | +$46.4K | ﹤0.01% | 5695 |
|
|
2017
Q1 | $3K | Sell |
322
-8,744
| -96% | -$85.4K | ﹤0.01% | 6909 |
|
|
2016
Q4 | $94K | Buy |
9,066
+9,041
| +36,164% | +$77.9K | ﹤0.01% | 5811 |
|
|
2016
Q3 | $0 | Sell |
25
-8,094
| -100% | -$68.8K | ﹤0.01% | 7040 |
|
|
2016
Q2 | $61K | Sell |
8,119
-14,991
| -65% | -$131K | ﹤0.01% | 5433 |
|
|
2016
Q1 | $208K | Buy |
23,110
+13,758
| +147% | +$112K | ﹤0.01% | 5052 |
|
|
2015
Q4 | $121K | Buy |
9,352
+8,642
| +1,217% | +$88.2K | ﹤0.01% | 5211 |
|
|
2015
Q3 | $7K | Sell |
710
-3,330
| -82% | -$30.6K | ﹤0.01% | 6585 |
|
|
2015
Q2 | $42K | Buy |
4,040
+940
| +30% | +$8.02K | ﹤0.01% | 5639 |
|
|
2015
Q1 | $34K | Sell |
3,100
-2,516
| -45% | -$26.8K | ﹤0.01% | 5766 |
|
|
2014
Q4 | $65K | Buy |
5,616
+5,334
| +1,891% | +$76.5K | ﹤0.01% | 5520 |
|
|
2014
Q3 | $6K | Buy |
282
+176
| +166% | +$4.04K | ﹤0.01% | 6472 |
|
|
2014
Q2 | $3K | Buy |
+106
| New | +$2.55K | ﹤0.01% | 6605 |
|
Other funds holding AKBA
VCM
VPM
Citigroup's AKBA Position: Q1 2026 in Review
Citigroup increased its Akebia Therapeutics (AKBA) stake by 17% in Q1 2026, buying an estimated $575K and bringing the position to 2,854,586 shares worth $3.97M. The position accounts for ﹤0.01% of the portfolio, ranked #2140.
Citigroup first reported a position in AKBA in Q2 2014 and has held it in 48 quarters since. The position peaked at $8.26M in Q2 2020. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.
- Citigroup held 2,854,586 shares of Akebia Therapeutics worth $3.97M as of Q1 2026.
- Citigroup bought 418,383 Akebia Therapeutics shares in Q1 2026, an estimated $575K.
- Akebia Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #2140 holding.
- Citigroup first reported a position in Akebia Therapeutics in Q2 2014 and has held it in 48 quarters since.
- Citigroup's Akebia Therapeutics position peaked at $8.26M in Q2 2020.
- 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.
Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.